Glycoprotein News and Research

RSS

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

Omicron will outcompete Delta variant for next 4-5 months globally: Genome study

A new study published in the pre-print server medRxiv* hypothesized that the emergence of more immune invasive or transmissible variants of SARS-CoV-2 was associated with increased genetic distinctiveness from the original or previous strains.

29 Dec 2021

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

29 Dec 2021

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.

29 Dec 2021

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

New data shows that, compared to adults, children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preferentially activate pre-existing acquired immunity to prevalent common cold coronaviruses that cross-react with SARS-CoV-2 and protect them from severe disease.

24 Dec 2021

COVID can affect sperm quality for three months

Researchers determine whether SARS-CoV-2 could cross the blood-testis barrier and be detected in human semen after infection.

22 Dec 2021

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.

22 Dec 2021

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

A new preprint research paper posted to the bioRxiv* server examines the nature and effects of the spike mutations and identifies a vulnerable point that could help develop broad-spectrum protection against circulating variants.

21 Dec 2021

Genomic study of furin cleavage sites validates the natural evolutionary origin of SARS-CoV-2 in bats

A team of researchers describes the genomic region encompassing the furin cleavage site in SARS-CoV-2.

20 Dec 2021

Production of functional SARS-CoV-2 spike protein in single-cell green alga

A new study uses a novel algal platform for the generation of the SARS-CoV-2 spike protein.

19 Dec 2021

New study demonstrates SARS-CoV-2 Omicron antibody escape

A new study examined the neutralization of virus variants using three sets of antibodies: serum from individuals vaccinated or infected with earlier variants of the virus; concentrated human antibodies from plasma donors; and approved monoclonal antibodies.

16 Dec 2021

Exploring the possibility of developing a plant-based oral vaccine against COVID-19

New research optimizes methods for the in-planta expression of the recombinant protein corresponding to the Receptor Binding Domain (RBD) subunit of the surface-exposed Spike glycoprotein of SARS-CoV-2.

15 Dec 2021

Glycoprotein News and Research

Small molecule identified as a SARS-CoV-2 inhibitor

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Oral bacteria-based SARS-CoV-2 vaccine platform

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Minimal nAb titers against Omicron in the elderly after 3rd dose

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Omicron will outcompete Delta variant for next 4-5 months globally: Genome study

Omicron analysis shows no clear evidence for increased virulence or lethality

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

COVID can affect sperm quality for three months

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Broad neutralization of SARS-CoV-2 spike protein by an unconventional antibody fragment

Genomic study of furin cleavage sites validates the natural evolutionary origin of SARS-CoV-2 in bats

Production of functional SARS-CoV-2 spike protein in single-cell green alga

New study demonstrates SARS-CoV-2 Omicron antibody escape

Exploring the possibility of developing a plant-based oral vaccine against COVID-19

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News